1. PRESENTED BY- NAVEEN KADIAN DEPARTMENT OF PHARMACEUTICAL CHEMISTRY K.L.E’S COLLEGE OF PHARMACY BELGAUM-10 2. CONTENTS • Introduction • Epidemiology of PD • Causes…

1. INDEX  INTRODUCTION PARKINSONIAN SYNDROMES DIFFERENTIAL DIAGNOSIS IN A PATIENT WITH PARKINSONIAN MANIFESTATIONSParkinsonism appears clinically in a variety of neurologic…

1. PARKINSON’S DISEASEHANDBOOK A GUIDE FOR PATIENTSAND THEIR FAMILIES Roger C. Duvoisin, MD William Dow Lovett Professor and Chairman Emeritus Lawrence I. Golbe, MD Associate…

1. PARKINSON’S DISEASE Muthuukaruppan M. 2. Parkinson’s diseaseParkinson’s disease Chronic, progressive disease characterized byChronic, progressive disease characterized…

1. • Also known as i. Parkinsons, ii. Idiopathic parkinsonism, iii. Primary parkinsonism, iv. PD, v. Paralysis agitans• a group of conditions called motor system disorders,…

1. - DR. SRIRAM.R 2.  Clonidine and Guanfacine  MOA - Stimulation of alpha2-adrenergic receptors reduces the firing rate of noradrenergic neurons and of plasma concentrations…

PowerPoint Presentation PARKINSONISM Niharika Agrawal Shweta Kolhatkar Ansu Chacko Chi-Hsin Yu What is parkinsonâs disease? It is a chronic progressive degenerative disorder…

Copyright 2012 Wolters Kluwer Health | Lippincott Williams & WilkinsChapter 21Drugs Treating Parkinson Disease and Other Movement Disorders Copyright 2012 Wolters Kluwer…

Slide 1 Slide 2 Antiparkinsoniandrugs(Abstract) Assoc. Prof. Iv. Lambev E-mail: [email protected] www.medpharm-sofia.eu J. Parkinson Slide 3 Parkinson’s disease (PD) is…

Slide 1 Rehabilitation Management of Parkinsons Disease Susan Stickevers, MD Residency Program Director & Assistant Clinical Professor, SUNY Stony Brook Dept of PM&R…